Search

1 to 9 of 9
Sort by

Library Entry
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

Checkpoint blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the response to anti-PD-1 immunotherapy in HCC are still unclear. The authors report the...


Library Entry
Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab

Recent data suggested a role of gut microbiota and antibiotic use on immune checkpoint inhibitors efficacy. The authors aimed to evaluate the impact of early use of antibiotic (EUA), blood microbiome and plasmatic citrulline (marker of the intestinal barrier) on nivolumab efficacy in non-small...




Library Entry
Exploring the emerging role of the microbiome in cancer immunotherapy

In this review the authors summarize 1) basic methodologies and considerations for studies of host-microbiota interactions; 2) experimental evidence towards a causal link between gut microbiota composition and immunotherapeutic efficacy; 3) possible mechanisms governing the microbiota-mediated...


Library Entry
Could the menagerie of the gut microbiome really cure cancer? Hope or hype

The investigational scale of the gut microbiome is expanding rapidly. In 2018, the intersection of gut microbiota and immuno-oncology received much attention. While the impact of gut microbiota on the immune system was already established, the year received an exponential expansion of microbiome...


Event
Adoptive Cellular Therapies Workshop

Sept. 5, 8 a.m. –5 p.m. | Sept. 6, 8 a.m. – 3:30 p.m. PROGRAM ORGANIZERS: Alessandra Cesano, MD, PhD – ESSA Pharma Inc. Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center In the wake of the 2017 U.S. Food and Drug Administration approvals for Chimeric Antigen...

 09-05-2019 08:00 - 09-06-2019 15:30 CT
 Houston TX


Event
Cancer Immune Responsiveness Workshop

Sept. 4, 8 a.m. – 6 p.m. | Sept. 5, 8 a.m. – 12:55 p.m.* *Lunch will be available until 2 p.m. Thursday following the workshop. PROGRAM ORGANIZERS Alessandra Cesano, MD, PhD – ESSA Pharma Inc. Francesco M. Marincola, MD – Refuge Biotechnologies, Inc. Building upon the success of...

 09-04-2019 08:00 - 09-05-2019 12:55 CT
 Houston TX


Web Page
Cancer Immune Responsiveness Workshop

Sept. 4–5, 2019 • Houston, Texas View Schedule Building upon the success of 2018’s Interim Workshop on Cancer Immune Responsiveness (CIR), the goal of this year’s CIR workshop was the continued advancement of knowledge in the field about interactions between the immune system and cancer...